Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on discovering, developing, and commercializing innovative pain treatments, today announced that researchers will be presenting scientific data on SPRIX® (ketorolac tromethamine) Nasal Spray, Egalet-001, an abuse-deterrent, extended-release, oral morphine product candidate, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product in development, at PainWeek 2015 to be held September 8 to 12 in Las Vegas, Nevada.
SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug (NSAID), is indicated in adult patients for the short-term (up to five days) management of moderate to moderately severe pain that requires analgesia at the opioid level, and is available with a prescription through Sprix Direct. Egalet's Guardian™ Technology product candidates Egalet-001 and Egalet-002 are in late-stage development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
"This is an exciting time for Egalet as we will be presenting efficacy data for one of our approved products, SPRIX Nasal Spray, showing how it is an effective treatment option compared to combination opioid products for adult patients with moderate to moderately severe short-term pain and data that demonstrates the abuse-deterrent profiles of our late-stage product candidates, Egalet-001 and Egalet-002, developed using our proprietary Guardian Technology," said Jeffrey Dayno, MD, Egalet's chief medical officer. "We look forward to sharing these data with those attending the upcoming PainWeek conference."
The following posters will be presented during the PainWeek 2015 poster session on Thursday, September 10 from 7:00 pm - 9:00 pm:
- Comparison of the Effect Sizes of Ketorolac Nasal Spray and Commonly Prescribed Oral Combination Opioids in Moderate to Severe Short-Term Pain (Poster #86), Authors: Gwendolyn Niebler, DO, Jeffrey Dayno, MD, and Robert Axford-Gatley, MD
- Extreme Work Requirement of EG-001, an Abuse-Deterrent, Extended-Release Morphine Product as Demonstrated With the ALERRTSM Visual Analog Scales (Poster #30), Authors: Edward J. Cone, PhD, August R. Buchhalter, PhD, Karsten Lindhardt, MSc, PhD, DBE, Torben Elhauge, MS, Jeffrey Dayno, MD
- Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (EG-001) Versus a Currently-Available non-AD, ER Morphine Product Administered Orally in Nondependent, Recreational Opioid Users (Poster #121), Authors: Michael Smith, PharmD, Lynn Webster, MD, John Lawler, BS, Jeffrey Dayno, MD
- Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (EG-001) Versus a Currently-Available non-AD, ER Morphine Product Administered Intranasally in Nondependent, Recreational Opioid Users (Poster #136), Authors: Lynn Webster, MD, Michael Smith, PharmD, John Lawler, BS, Jeffrey Dayno, MD
- EG-002, a Novel Proprietary Abuse-Deterrent, Extended-Release Formulation of Oxycodone Demonstrates Strong Abuse-Deterrent Potential Based on the Results From a Category 1 In Vitro Physical Manipulation Study (Poster #31), Authors: Edward J. Cone, PhD, August R. Buchhalter, PhD, Karsten Lindhardt, MSc, PhD, DBE, Torben Elhauge, MS, Jeffrey Dayno, MD